Abstract
Finely tuned gamma oscillations have been recorded from the subthalamic nucleus and cortex in Parkinson’s disease patients undergoing deep brain stimulation and are often associated with dyskinesia. More recently, it was shown that deep brain stimulation entrains finely tuned gamma to ½ of the stimulation frequency; however, the functional role of this signal is not yet fully understood.
We recorded local field potentials from the subthalamic nucleus in 19 chronically implanted Parkinson’s disease patients under effective dopaminergic medication and during deep brain stimulation with increasing stimulation amplitude, while they were at rest and during repetitive hand movements. We analyzed the effect of stimulation intensity on gamma band 1:2 entrainment and compared the entrained signal during rest and during repetitive movement.
Spontaneous finely tuned gamma was present in eight out of 19 patients (peak frequency μ = 78.4 ±4.3 Hz). High-frequency deep brain stimulation induced 1:2 gamma entrainment in 15 out of 19 patients. Entrainment occurred at a mean stimulation amplitude of 2.2 0.75 mA and disappeared or decreased in power during higher stimulation amplitude in three patients. In patients with spontaneous finely tuned gamma, increasing the stimulation amplitude induced a progressive frequency shift of spontaneous finely tuned gamma until it locked to 1:2 entrainment. Only five out of 15 patients with entrained gamma activity showed dyskinesia during stimulation. Further, there was a significant increase in the power of 1:2 entrained gamma activity during movement in comparison to rest. Finally, patients with entrained gamma activity had faster movements as compared to those without gamma entrainment.
These findings argue for a functional relevance of the stimulation-induced 1:2 gamma entrainment in Parkinson’s disease patients as a prokinetic activity that, however, is not necessarily promoting dyskinesia. Previously published electrophysiological models of entrainment fit well to our results and support our findings that stimulation-induced entrainment can be a promising real-life biomarker for closed-loop deep brain stimulation.
Competing Interest Statement
A.A.K. received honoraria for consultancies and/or talks from Medtronic, Boston Scientific, and Stada Pharm. L.K.F. received honoraria for consultancies/talks from Medtronic. The remaining authors report no competing interests.
Funding Statement
A.A.K. received funding from the Lundbeck Foundation as part of the collaborative project grant 'Adaptive and precise targeting of cortex-basal ganglia circuits in Parkinson's Disease' (Grant Nr. R336-2020-1035), from the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) - Project-ID 424778381 - TRR 295, and from the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany's Excellence Strategy - EXC-2049 - 390688087. J.H., J.R. and J.L.B. are fellows of the BIH Charité Junior Clinician Scientist Program.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol was approved by the local ethics committee (Medical Ethical Committee of Charit169 cl:1 Universitätsmedizin, Berlin, Germany, Protocol ID.: EA2/256/60) in accordance with the standards set by the Declaration of Helsinki.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
